

Table S1. Characteristics of confirmed COVID-19 cases and deaths in Mexico until Aug/06/2020 (first cutoff).

	Cases		Deaths		% mCFR	RR _d [95% CI] ^a	Mortality (100,000 inh.) ^b
	n (%)	Age	n (%)	Age			
Males	245,583 (53.1)	45.8±16.5	32,707 (64.7)	61.1±14.0	13.32	1.62 [1.60-1.65]****	51.8
Females	217,107 (46.9)	44.4±16.4	17,810 (35.3)	62.8±14.3	8.20	0.62 [0.61-0.63]****	27.0
Total	462,690 (100)	45.1±16.4	50,517 (100)	61.7±14.2	10.92	-	39.1
Age group (years old)							
0-1	1,596 (0.3)	-	78 (0.2)	-	4.89	0.45 [0.36-0.55]****	
2-9	3,216 (0.7)	-	44 (0.1)	-	1.37	0.13 [0.09-0.17]****	0.5
10-19	10,992 (2.4)	-	85 (0.2)	-	0.77	0.07 [0.06-0.09]****	0.3
20-29	66,745 (14.4)	-	614 (1.2)	-	0.92	0.07 [0.07-0.08]****	2.8
30-39	103,293 (22.3)	-	2,344 (4.6)	-	2.27	0.17 [0.16-0.18]****	12.4
40-49	101,647 (22.0)	-	6,377 (12.6)	-	6.27	0.51 [0.50-0.53]****	38.6
50-59	83,567 (18.1)	-	11,688 (23.1)	-	13.99	1.37 [1.34-1.39]****	93.2
60-69	52,327 (11.3)	-	13,827 (27.4)	-	26.42	2.96 [2.91-3.01]****	171.1
70-79	27,270 (5.9)	-	10,254 (20.3)	-	37.60	4.07 [3.99-4.14]****	252.1
80-89	10,379 (2.2)	-	4,521 (8.9)	-	43.56	4.28 [4.18-4.39]****	274.6
≥90	1,658 (0.4)	-	685 (1.4)	-	41.31	3.82 [3.60-4.05]****	181.7
Total	462,690 (100)		50,517 (100)		10.92	-	
Clinical condition							
Not hospitalized	338,693 (73.2)	41.2±14.7	5696 (11.3)	60.8±14.4	1.68	0.05 [0.045-0.048]****	ND
Hospitalized	123,997 (26.8)	56.0±16.1	44,821 (88.7)	61.8±14.1	36.15	21.5 [20.93-22.08]****	ND
Unknown condition	116 (0.03)	55.2±16.5	69 (0.1)	59.4±17.1	59.48	-	ND
Not critical ^c	107,145 (23.2)	55.8±16.1	34,749 (68.8)	62.4±14.0	32.43	19.3 [18.77-19.82]****	ND
Critical	16,736 (3.6)	56.9±16.4	10,003 (19.8)	59.9±14.4	59.77	35.5 [34.54-36.57]****	ND
AMV	11,928 (2.6)	58.0±15.3	8,642 (17.1)	59.7±14.2	72.45	43.1 [41.89-44.30]****	ND
Confirmed Pneumonia	94,133 (20.3)	55.9±15.8	37,699 (74.6)	61.7±14.1	40.05	11.5 [11.30-11.73]****	ND
Number of comorbidities							
0	249,308 (53.9)	40.2±15.1	13,467 (26.7)	59.6±15.0	5.40	0.31 [0.30-0.32]****	ND
1	122,233 (26.4)	47.4±15.8	15,056 (29.9)	61.3±14.6	12.32	2.28 [2.23-2.33]****	ND
2	59,246 (12.8)	54.4±15.3	12,513 (24.8)	63.2±13.3	21.12	3.91 [3.82-4.00]****	ND
≥3	30,016 (6.5)	58.6±13.9	9,146 (18.1)	63.6±12.6	30.47	5.64 [5.51-5.78]****	ND
unknown	1,887 (0.4)	47.4±16.6	335 (0.7)	59.0±14.8	17.75	-	ND
Total	462,690 (100)		50,517 (100)		10.92	-	
Total with known comorbidity status	460,803 (99.6)		50,182 (99.3)		10.89	-	

^aRR of death was calculated for males vs females; pregnant females vs 20-39 yo non-pregnant females; indigenous language speakers vs non-speakers; each age group vs the rest of the population; not hospitalized vs hospitalized and *vice versa*; other clinical conditions vs not hospitalized; having vs not having confirmed pneumonia; having no comorbidity (0) vs having some comorbidity (≥1); having 1, 2, ≥3 comorbidities vs no comorbidity. **** p < 0.0001, *** p < 0.001, CI= Confidence interval.

^b Mortality corresponds to COVID-19 deaths until Aug 06, 2020 and has increased since. ND=not determined.

^c “Not critical” means that the patient was not treated in the ICU (Intensive Care Unit) and was not intubated outside the ICU up until the cutoff date (Aug/06/2020). “Critical” patients were those treated in the ICU or that required intubation and mechanical ventilation even if they were not in the ICU.

Table S2. Characteristics of confirmed COVID-19 cases and deaths in Mexico until Sept/12/2020 (second cutoff).

	Cases		Deaths		% mCFR	RR [95% CI] ^a	Mortality (100,000 inh.) ^b
	n (%)	Age	n (%)	Age			
Males	346,464 (52.2)	45.5± 16.7	45,413 (64.3)	61.7± 14.1	13.11	1.65 [1.63-1.68]****	72.0
Females	317,509 (47.8)	44.1± 16.5	25,191 (35.7)	63.3± 14.2	7.93	0.61 [0.60-0.61]****	38.2
Total	663,973 (100)	44.8± 16.6	70,604 (100)	62.2± 14.2	10.63	-	54.8
Age group (years old)							
0-1	2,233 (0.3)	-	107 (0.2)	-	4.79	0.45 [0.37-0.54]****	
2-9	5,032 (0.8)	-	52 (0.1)	-	1.03	0.10 [0.07-0.13]****	
10-19	17,926 (2.7)	-	12 (0.2)	-	0.67	0.06 [0.05-0.07]****	0.5
20-29	100,792 (15.2)	-	851 (1.2)	-	0.84	0.07 [0.06-0.07]****	3.9
30-39	147,859 (22.3)	-	3,081 (4.4)	-	2.08	0.16 [0.15-0.17]****	16.4
40-49	143,051 (21.5)	-	8,468 (12.0)	-	5.92	0.50 [0.49-0.51]****	51.3
50-59	117,449 (17.7)	-	15,836 (22.4)	-	13.48	1.35 [1.32-1.37]****	126.4
60-69	73,679 (11.1)	-	19,529 (27.7)	-	26.51	3.06 [3.02-3.11]****	243.2
70-79	38,765 (5.8)	-	14,915 (21.1)	-	38.48	4.32 [4.26-4.38]****	366.8
80-89	14,816 (2.2)	-	6,660 (9.4)	-	44.95	4.56 [4.48-4.65]****	404.6
≥90	2,371 (0.4)	-	984 (1.4)	-	41.50		261.1
Total	663,973 (100)		70,604 (100)		10.63	3.94 [3.76-4.14]****	
Clinical condition							
Not hospitalized	500,193 (75.3)	41.0± 14.9	8,110 (11.5)	61.4± 14.4	1.62	0.04 [0.04-0.04]****	ND
Hospitalized	163,780 (24.7)	56.5± 16.3	62,494 (88.5)	62.4± 14.1	38.16	23.5 [23.01-24.07]****	ND
Unknown condition	152 (0.02)	56.2± 15.3	74 (0.1)	59.5± 16.1	48.68	-	ND
Not critical ^c	127,337 (19.2)	55.9± 16.4	36,644 (51.9)	63.4± 14.1	28.78	17.8 [17.34-18.17]****	ND
Critical	36,291 (5.5)	58.4± 15.7	25,776 (36.5)	60.9± 14.0	71.03	43.8 [42.83-44.81]****	ND
AMV	29,850 (4.5)	59.3± 14.9	24,065 (34.1)	60.8± 13.9	80.62	49.7 [48.63-50.84]****	ND
Confirmed Pneumonia	125,765 (18.9)	56.4± 16.0	52,398 (74.2)	62.2± 14.1	41.66	12.3 [12.12-12.51]****	ND
Number of comorbidities							
0	362,425 (54.6)	39.8± 15.3	18,553 (26.3)	60.1± 15.0	5.12	0.30 [0.29-0.30]****	ND
1	174,141 (26.2)	47.3± 16.0	20,975 (29.7)	61.9± 14.6	12.04	2.35 [2.31-2.40]****	ND
2	83,165 (12.5)	54.5± 15.4	17,703 (25.1)	63.7± 13.3	21.29	4.16 [4.08-4.24]****	ND
≥3	41,523 (6.3)	58.8± 14.0	12,908 (18.3)	64.0± 12.7	31.09	6.07 [5.95-6.20]****	ND
unknown	2,719 (0.4)	46.9± 17.0	465 (0.7)	59.2± 15.5	17.10	-	ND
Total	663,973 (100)		70,604 (100)		10.63	-	
Total with known comorbidity status	661,254 (99.6)		70,139 (99.3)		10.61	-	

^aRRd were calculated as for Supplementary Table 1. **** p < 0.0001, ** p < 0.001, CI= Confidence interval.

^b Mortality depicted here corresponds to COVID-19 deaths until Sep 12, 2020 and has increased since.

^c “Not critical” means that the patient was not treated in the ICU (Intensive Care Unit) and was not intubated outside the ICU up until the cutoff date (Sep/12/2020). “Critical” patients were those treated in the ICU or that required intubation and mechanical ventilation even if they were not in the ICU.

Table S3. Characteristics of confirmed COVID-19 cases and deaths in Mexico until Nov/2/2020 (end of study).

	Cases		Deaths		% mCFR	RR _d [95% CI] ^a	Mortality (100,000 inh.) ^b
	n (%)	Age	n (%)	Age			
Males	465,079 (51.4)	45.0±16.9	56,916 (63.8)	62.1±14.2	12.24	1.67 [1.65-1.69]****	90.2
Females	440,500 (48.6)	43.7±16.5	32,251 (36.2)	63.5±14.2	7.32	0.60 [0.59-0.61]****	49.0
Total	905,579 (100)	44.4±16.7	89,167 (100)	62.6±14.2	9.85	-	69.2
Age group (years old)							
0-1	2,943 (0.3)	-	132 (0.1)	-	4.49	0.45 [0.38-0.54]****	-
2-9	7,172 (0.8)	-	67 (0.1)	-	0.93	0.09 [0.07-0.12]****	-
10-19	27,492 (3.0)	-	156 (0.2)	-	0.57	0.06 [0.05-0.07]****	0.7
20-29	145,299 (16.0)	-	1,063 (1.2)	-	0.73	0.06 [0.06-0.07]****	4.9
30-39	201,362 (22.2)	-	3,744 (4.2)	-	1.86	0.15 [0.15-0.16]****	19.9
40-49	192,365 (21.2)	-	10,314 (11.6)	-	5.36	0.49 [0.48-0.49]****	62.4
50-59	157,082 (17.3)	-	19,546 (21.9)	-	12.44	1.34 [1.32-1.36]****	156.0
60-69	97,716 (10.8)	-	24,709 (27.7)	-	25.29	3.17 [3.13-3.21]****	307.7
70-79	51,337 (5.7)	-	19,322 (21.7)	-	37.64	4.60 [4.54-4.66]****	475.1
80-89	19,642 (2.2)	-	8,787 (9.9)	-	44.74	4.93 [4.85-5.01]****	533.8
≥90	3,169 (0.3)	-	1,327 (1.5)	-	41.87	4.30 [4.13-4.48]****	352.1
Total	905,579 (100)		89,167 (100)		9.85	-	
Clinical condition							
Not hospitalized	701,279 (77.4)	40.7±15.0	9,690 (10.9)	61.7±14.4	1.38	0.04 [0.03-0.04]****	ND
Hospitalized	204,300 (22.6)	56.8±16.4	79,477 (89.1)	62.7±14.2	38.90	28.2 [27.58-28.74]****	ND
Unknown condition	589 (0.07)	59.7±15.1	495 (0.6)	60.7±15.1	84.04	-	ND
Not critical ^c	161,850 (17.9)	56.3±16.5	49,282 (55.3)	63.7±14.1	30.45	22.0 [21.58-22.51]****	ND
Critical	41,853 (4.6)	58.6±15.7	29,692 (33.3)	61.1±14.1	70.94	51.3 [50.29-52.42]****	ND
AMV	33,738 (3.7)	59.4±14.9	27,381 (30.7)	60.9±14.0	81.16	58.7 [57.55-59.95]****	ND
Confirmed Pneumonia	155,429 (17.2)	56.7±16.1	65,412 (73.4)	62.6±14.1	42.08	13.3 [13.11-13.47]****	ND
Number of comorbidities							
0	505,783 (55.9)	39.4±15.3	23,174 (26.0)	60.6±15.1	4.58	0.28 [0.27-0.28]****	ND
1	232,890 (25.7)	47.0±16.1	26,244 (29.4)	62.2±14.7	11.27	2.46 [2.42-2.50]****	ND
2	108,992 (12.0)	54.4±15.5	22,386 (25.1)	64.0±13.4	20.54	4.48 [4.41-4.56]****	ND
≥3	53,979 (6.0)	59.0±14.0	16,806 (18.8)	64.3±12.6	31.13	6.80 [6.68-6.92]****	ND
unknown	3,935 (0.4)	45.8±16.9	557 (0.6)	60.1±15.6	14.16	-	ND
Total	905,579 (100)		89,167 (100)		9.85	-	
Total with known comorbidity status	901,644 (99.6)		88,610 (99.4)		9.83	-	

^a RR_d was calculated as in table 1. **** p < 0.0001, ** p < 0.001, CI= Confidence interval.

^b Mortality depicted here corresponds to COVID-19 deaths until Oct 4, 2020 and has increased since.

^c “Not critical” means that the patient was not treated in the ICU (Intensive Care Unit) and was not intubated outside the ICU up until the cutoff date (Oct/4/2020). “Critical” patients were those treated in the ICU or that required intubation and mechanical ventilation even if they were not in the ICU.

Table S4. Age of COVID-19 cases and deaths in Mexico subdivided by the presence/absence of comorbidity, until Aug/06/2020 (first cutoff).

	Age of Cases ^a			Age of deaths ^a		
	without comorbidity	with comorbidity ^b	<i>p</i> ^c	without comorbidity	with comorbidity ^b	<i>p</i> ^d
<i>Clinical conditions (all genders)</i>						
Not hospitalized	38.0 ± 13.7	46.3 ± 14.8	****	58.8 ± 15.4	61.7 ± 13.9	****
Hospitalized	51.2 ± 17.1	58.6 ± 15.1	****	59.7 ± 15.0	62.7 ± 13.8	****
Not critical ^e	51.1 ± 16.9	58.5 ± 15.1	****	60.5 ± 14.7	63.2 ± 13.8	****
Critical ^e	52.2 ± 18.8	58.9 ± 14.9	****	57.1 ± 15.7	61.0 ± 13.8	****
Intubated ^e	54.3 ± 17.1	59.6 ± 14.3	****	56.7 ± 15.3	60.9 ± 13.6	****
Confirmed Pneumonia	51.0 ± 16.6	58.5 ± 14.9	****	59.7 ± 14.9	62.5 ± 13.8	****
<i>Genders</i>						
Males	41.3 ± 15.6	51.0 ± 16.1	****	59.3 ± 14.7	62.0 ± 13.8	****
Females	39.0 ± 14.7	51.0 ± 16.0	****	60.4 ± 15.9	63.5 ± 13.8	****
Total	40.2 ± 15.2	51.0 ± 16.1	****	59.6 ± 15.0	62.6 ± 13.8	****

^a Ages and standard deviation correspond to cases and deaths with known comorbidity status.

^b These patients had the diagnosis of at least one chronic comorbidity.

^c Two-tailed comparison of the ages of cases with vs without comorbidity;

^d Two tailed comparison of the ages of individuals that died, with vs without comorbidity.

**** *p* > 0.0001; ns, not significant.

^e “Not critical” refers to patients that were not in the ICU or intubated until cutoff date. “Critical” refers to patients treated in ICU or intubated. For simplicity, only the intubated patients, and not all categories of the critical patients, are shown.

Indigenous LS, Indigenous language speakers

Table S5. Frequency, CFR and RR of COVID-19 death (RR_d) of specific chronic comorbidities, by gender, in Mexico, until Aug/06/2020 (first cutoff).

	Cases n (%)	Deaths n (%)	As a single comorbidity		In combination with one other comorbidity		In combination with ≥2 other comorbidities	
			%m CFR	RR _d [95% CI] ^a	%m CFR	RR _d [95% CI] ^a	%m CFR	RR _d [95% CI] ^a
Males								
Obesity	44,118 (38.6)	7,342 (32.3)	10.9	1.5 [1.39-1.52]****	16.6	2.2 [2.13-2.31]****	29.5	4.0 [3.81-4.10]****
Diabetes	39,594 (34.6)	11,353 (49.9)	22.1	3.0 [2.85-3.08]****	29.0	3.9 [3.77-4.01]****	35.1	4.7 [4.56-4.85]****
HT	48,110 (42.1)	12,919 (56.8)	20.4	2.7 [2.63-2.84]****	27.0	3.6 [3.51-3.73]****	34.0	4.6 [4.42-4.70]****
CVD	5,550 (4.9)	1,681 (7.4)	18.0	2.4 [2.09-2.76]****	26.7	3.6 [3.29-3.89]****	35.9	4.8 [4.57-5.07]****
CKD	5,152 (4.5)	2,031 (8.9)	21.8	2.9 [2.54-3.35]****	35.5	4.8 [4.41-5.13]****	45.1	6.1 [5.79-6.31]****
Smoker	23,490 (20.6)	3,451 (15.2)	6.7	0.9 [0.83-0.96]**	15.6	2.1 [1.97-2.21]****	31.4	4.2 [4.02-4.40]****
Asthma	4,824 (4.2)	469 (2.1)	4.1	0.6 [0.45-0.67]****	11.0	1.5 [1.26-1.70]****	20.2	2.7 [2.40-3.05]****
COPD	3,747 (3.3)	1,375 (6.0)	27.9	3.7 [3.31-4.21]****	34.8	4.7 [4.29-5.07]****	41.0	5.5 [5.18-5.81]****
ImmunoS	2,608 (2.3)	732 (3.2)	17.7	2.4 [2.01-2.78]****	24.9	3.3 [2.94-3.77]****	36.5	4.9 [4.52-5.29]****
Other	5,309 (4.6)	1,503 (6.6)	19.5	2.6 [2.39-2.87]****	27.8	3.7 [3.43-4.03]****	38.7	5.2 [4.86-5.51]****
Individuals w/comorb ^b	114,322 (100)	22,756 (100)	14.9	2.0 [1.94-2.05]****	23.9	3.2 [3.11-3.29]****	33.4	4.5 [4.35-4.61]****
Females								
Obesity	42,611 (43.9)	5,113 (36.6)	5.4	1.7 [1.59-1.81]****	12.5	4.0 [3.75-4.20]****	24.4	7.7 [7.38-8.10]****
Diabetes	34,177 (35.2)	7,775 (55.7)	15.8	5.0 [4.74-5.32]****	22.0	7.0 [6.68-7.30]****	29.0	9.2 [8.80-9.59]****
HT	43,354 (44.6)	9,170 (65.7)	14.3	4.5 [4.29-4.77]****	21.0	6.6 [6.37-6.93]****	28.4	9.0 [8.63-9.39]****
CVD	4,174 (4.3)	997 (7.1)	9.8	3.1 [2.48-3.89]****	17.6	5.6 [1.94-2.05]****	30.7	9.7 [9.1-10.42]****
CKD	3,963 (4.1)	1,372 (9.8)	14.9	4.7 [3.86-5.74]****	28.3	9.0 [8.03-9.97]****	41.4	13.1 [12.4-13.9]****
Smoker	9,827 (10.1)	643 (4.6)	1.8	0.6 [0.47-0.71]****	6.4	2.0 [1.76-2.34]****	17.9	5.7 [5.13-6.24]****
Asthma	7,522 (7.7)	564 (4.0)	2.8	0.9 [0.74-1.09] ^{ns}	6.3	2.0 [1.69-2.36]****	17.4	5.5 [4.96-6.09]****
COPD	3,464 (3.6)	1,051 (7.5)	23.1	7.3 [6.27-8.49]****	26.6	8.4 [7.57-9.36]****	34.6	11.0 [10.2-11.8]****
ImmunoS	2,846 (2.9)	603 (4.3)	11.3	3.6 [2.95-4.33]****	18.5	5.9 [5.04-6.80]****	29.8	9.4 [8.6-10.33]****
Other	6,362 (6.6)	1,093 (7.8)	8.1	2.6 [2.23-2.92]****	16.7	5.3 [4.75-5.90]****	29.1	9.2 [8.55-9.93]****
Individuals w/comorb ^b	97,173 (100)	13,959 (100)	9.2	2.9 [2.81-3.05]****	17.9	5.7 [5.45-5.91]****	27.9	8.7 [8.31-9.02]****
Total								
Obesity	86,729 (41.0)	12,455 (33.9)	8.2	1.5 [1.46-1.57]****	14.7	2.7 [2.62-2.81]****	26.8	5.0 [4.83-5.11]****
Diabetes	73,771 (34.9)	19,128 (52.1)	19.5	3.6 [3.49-3.72]****	25.7	4.8 [4.64-4.88]****	32.1	5.9 [5.79-6.09]****
HT	91,464 (43.2)	22,089 (60.2)	17.6	3.3 [3.16-3.35]****	24.1	4.5 [4.36-4.58]****	31.3	5.8 [5.65-5.93]****
CVD	9,724 (4.6)	2,678 (7.3)	14.5	2.7 [2.37-3.01]****	23.1	4.3 [3.97-4.58]****	33.6	6.2 [5.98-6.48]****
CKD	9,115 (4.3)	3,403 (9.3)	18.8	3.5 [3.10-3.90]****	32.5	6.0 [5.65-6.40]****	43.5	8.1 [7.78-8.33]****
Smoker	33,317 (15.8)	4,094 (11.2)	5.2	1.0 [0.9-1.04] ^{ns}	12.9	2.4 [2.27-2.52]****	27.5	5.1 [4.88-5.30]****
Asthma	12,346 (5.8)	1,033 (2.8)	3.4	0.6 [0.54-0.71]****	8.2	1.5 [1.35-1.69]****	18.4	3.4 [3.15-3.67]****
COPD	7,211 (3.4)	2,426 (6.6)	25.7	4.8 [4.33-5.23]****	30.9	5.7 [5.35-6.10]****	37.9	7.0 [6.71-7.32]****
ImmunoS	5,454 (2.6)	1,335 (3.6)	14.2	2.6 [2.32-2.97]****	21.6	4.0 [3.64-4.40]****	33.1	6.1 [5.76-6.49]****
Other	11,671 (5.5)	2,596 (7.1)	13.0	2.4 [2.23-2.61]****	22.0	4.1 [3.81-4.34]****	33.5	6.2 [5.91-6.51]****
Individuals w/comorb ^b	211,495 (100)	36,715 (100)	12.3	2.3 [2.23-2.33]****	21.1	3.9 [3.82-3.99]****	31.1	5.6 [5.51-5.78]****

^a All RRs were calculated against individuals with no comorbidities, in the same gender, excluding individuals with unknown comorbidity status **** p<0.0001; ** p<0.01; ns, not significant; CI, confidence interval.

^b Some patients had more than one comorbidity, thus the sum of comorbidities (n and %) is larger than the individuals with comorbidity (w/comorb). Percents were calculated using “individuals w/comorbidity” as 100%.

Table S6. Frequency, measured case fatality rate (mCFR) and relative risk of death (RR_d) of specific comorbidities by age group, in COVID-19 in Mexico until August/6/2020 (**first cutoff**).

Comorbidity /Age group	Cases n (%)	Deaths n (%)	As a single comorbidity		In combination with 1 other comorbidity		In combination with ≥2 other comorbidities	
			%m	RR [95% CI]	%m	RR [95% CI]	%m	RR [95% CI]
			CFR	RR [95% CI]	CFR	RR [95% CI]	CFR	RR [95% CI]
0-19 yo								
Obesity	839 (44.3)	18 (18.0)	1.8	2.3 [1.3-4.17]**	2.9	3.7 [1.43-9.5]**	4.4	5.6 [1.52-18.9]**
Diabetes	151 (8.0)	8 (8.0)	1.2	1.6 [0.27-8.5] ^{ns}	9.1	11.6 [4.5-27.7]****	12.0	15.3 [5.3-39.2]****
HT	124 (6.6)	9 (9.0)	4.4	5.6 [1.5-18.9]**	9.8	12.5 [4.9-29.5]****	8.1	10.4 [3.5-27.8]****
CVD	154 (8.1)	8 (8.0)	3.5	4.4 [1.5-12.6]**	5.9	7.5 [2.6-20.7]****	12.5	16.0 [4.4-47.1]****
CKD	93 (4.9)	11 (11.0)	4.4	5.6 [1.5-18.9]**	26.9	34.4 [17.1-61.3]****	4.8	6.1 [1.07-29.4]*
Smoker	266 (14.0)	2 (2.0)	-	-	4.3	5.4 [1.5-18.5]**	-	-
Asthma	567 (29.9)	2 (2.0)	0.4	0.55 [0.15-2.0] ^{ns}	-	-	-	-
COPD ^b	16 (0.8)	0 (0.0)	-	-	-	-	-	-
ImmunoS	311 (16.4)	28 (28.0)	5.6	7.1 [3.8-13.1]****	13.3	17.0 [9.8-28.4]****	15.2	19.4 [8.3-40.7]****
Other	449 (23.7)	54 (54.0)	12.5	15.9 [11.0-22.8]****	11.2	14.3 [8.5-23.5]****	11.8	15.0 [5.9-34.9]****
Individuals w/comorb ^c	1,894 (100)	100 (100)	3.3	4.2 [3.1-5.65]****	7.8	10.0 [6.6-15.05]****	9.5	12.1 [5.8-24.0]****
20-39 yo								
Obesity	27,478 (53.0)	1,032 (55.4)	3.0	3.2 [2.9-3.58]****	4.2	4.6 [4.0-5.2]****	9.5	10.4 [9.0-12.1]****
Diabetes	5,954 (11.5)	541 (29.1)	6.4	7.0 [6.0-8.25]****	8.8	9.6 [8.23-11.2]****	14.5	16.0 [13.8-18.4]****
HT	8,213 (15.8)	564 (30.3)	2.9	3.2 [2.6-3.94]****	7.2	8.0 [6.9-9.1]****	12.9	14.1 [12.4-16.2]****
CVD	1,089 (2.1)	67 (3.6)	2.6	2.9 [1.61-5.1]**	3.6	4.0 [2.3-6.9]****	13.0	14.3 [10.7-18.8]****
CKD	1,579 (3.0)	275 (14.8)	9.8	10.8 [8.3-14.0]****	19.0	20.9 [17.5-24.9]****	24.0	26.3 [22.1-31.1]****
Smoker	14,125 (27.2)	228 (12.2)	0.6	0.7 [0.5-0.91]**	2.5	2.7 [2.2-3.4]****	6.9	7.6 [6.0-9.5]****
Asthma	4,994 (9.6)	97 (5.2)	0.9	1.0 [0.66-1.4] ^{ns}	2.8	3.1 [2.2-4.2]****	5.9	6.6 [4.55-9.1]****
COPD ^b	395 (0.8)	33 (1.8)	3.2	3.5 [1.37-8.7]**	4.7	5.2 [2.4-10.8]****	16.2	17.8 [12.1-25.5]****
ImmunoS	1,130 (2.2)	128 (6.9)	6.2	6.8 [4.70-9.8]****	9.9	10.9 [7.8-15.05]****	18.7	20.6 [16.4-25.5]****
Other	2,942 (5.7)	159 (8.5)	2.9	3.2 [2.4-4.25]****	6.4	7.0 [5.4-9.2]****	12.8	14.0 [10.9-17.8]****
Individuals w/comorb ^c	51,869 (100)	1,862 (100)	2.6	2.8 [2.6-3.09]****	5.3	5.9 [5.3-6.5]****	11.9	13.1 [11.6-14.7]****
40-59 yo								
Obesity	41,075 (44.2)	5,383 (42.8)	9.5	1.6 [1.54-1.71]****	12.7	2.2 [2.1-2.3]****	20.7	3.5 [3.4-3.7]****
Diabetes	34,772 (37.4)	6,574 (52.3)	15.1	2.8 [2.45-2.71]****	17.9	3.1 [2.9-3.2]****	24.6	4.2 [4.0-4.4]****
HT	40,419 (43.5)	6,488 (51.6)	9.3	1.6 [1.49-1.68]****	16.3	2.8 [2.7-2.9]****	23.8	4.1 [3.9-4.2]****
CVD	3,099 (3.3)	546 (4.3)	8.2	1.4 [1.06-1.83]*	12.4	2.1 [1.8-2.5]****	23.6	4.0 [3.7-4.4]****
CKD	3,438 (3.7)	1,226 (9.8)	20.6	3.5 [2.92-4.19]****	29.3	5.0 [4.5-5.6]****	41.2	7.1 [6.65-7.45]****
Smoker	12,250 (13.2)	1,353 (10.8)	5.5	0.9 [0.84-1.06] ^{ns}	11.8	2.0 [1.85-2.2]****	19.8	3.4 [3.1-3.65]****
Asthma	4,907 (5.3)	438 (3.5)	4.3	0.7 [0.59-0.90]**	8.1	1.4 [1.2-1.6]****	15.9	2.7 [2.4-3.1]****
COPD	1,911 (2.6)	425 (3.4)	17.1	2.9 [2.34-3.61]****	15.8	2.7 [2.2-3.3]****	28.2	4.8 [4.3-5.3]****
ImmunoS	2,219 (2.4)	462 (3.7)	13.9	2.4 [1.95-2.89]****	17.0	2.9 [2.4-3.45]****	27.8	4.8 [4.3-5.3]****
Other	4,707 (5.1)	817 (6.5)	11.4	1.9 [1.70-2.21]****	15.6	2.7 [2.35-3.0]****	26.1	4.5 [4.1-4.9]****
Individuals w/comorb ^b	92,928 (100)	12,569 (100)	10.3	1.8 [1.70-1.83]****	15.3	2.6 [2.5-2.7]****	23.3	4.0 [3.8-4.1]****
60-79 yo								
Obesity	15,869 (28.6)	5,381 (29.5)	28.0	1.16 [1.10-1.23]****	32.3	1.34 [1.28-1.40]****	37.8	1.57 [1.52-1.63]****
Diabetes	29,225 (52.7)	10,330 (56.7)	30.2	1.26 [1.20-1.31]****	34.4	1.43 [1.38-1.48]****	39.7	1.65 [1.60-1.71]****
HT	36,287 (65.4)	12,146 (66.6)	27.6	1.15 [1.10-1.19]****	33.1	1.38 [1.33-1.42]****	39.1	1.63 [1.57-1.68]****
CVD	4,202 (7.6)	1,530 (8.4)	26.8	1.11 [0.95-1.30] ^{ns}	32.0	1.33 [1.21-1.46]****	39.6	1.65 [1.56-1.73]****
CKD	3,438 (6.2)	1,592 (8.7)	35.2	1.47 [1.21-1.74]**	43.9	1.83 [1.67-1.99]****	47.8	2.00 [1.90-2.10]****
Smoker	5,724 (10.3)	2,065 (11.3)	29.7	1.24 [1.14-1.34]****	33.8	1.41 [1.31-1.51]****	40.9	1.70 [1.61-1.79]****
Asthma	1,656 (3.0)	428 (2.3)	22.0	0.92 [0.75-1.11] ^{ns}	23.8	0.99 [0.83-1.16] ^{ns}	28.5	1.19 [1.06-1.32]**
COPD	3,591 (6.5)	1,395 (7.7)	29.8	1.24 [1.08-1.41]**	36.6	1.52 [1.40-1.65]****	42.3	1.76 [1.66-1.86]****
ImmunoS	1,550 (2.8)	593 (3.3)	28.5	1.18 [0.97-1.43] ^{ns}	35.1	1.46 [1.28-1.66]****	42.7	1.78 [1.64-1.92]****
Other	2,919 (5.3)	1,213 (6.7)	37.4	1.56 [1.40-1.72]****	40.7	1.69 [1.56-1.84]****	43.9	1.83 [1.71-1.94]****
Individuals w/comorb ^b	55,466 (100)	18,234 (100)	28.8	1.20 [1.16-1.23]****	33.8	1.40 [1.36-1.45]****	39.2	1.63 [1.58-1.68]****
≥80 yo								
Obesity	1,468 (16.7)	641 (16.2)	41.2	1.07 [0.91-1.25] ^{ns}	43.4	1.13 [1.01-1.26]*	44.5	1.16 [1.06-1.27]**
Diabetes	3,669 (41.8)	1,675 (42.4)	44.0	1.15 [1.04-1.26]**	45.2	1.18 [1.10-1.26]****	46.9	1.21 [1.14-1.31]****
HT	6,421 (73.2)	2,882 (73.0)	43.4	1.13 [1.06-1.21]****	44.8	1.17 [1.10-1.24]****	46.9	1.22 [1.14-1.31]****
CVD	1,180 (13.5)	527 (13.3)	48.1	1.25 [1.03-1.49]*	43.0	1.12 [0.98-1.27] ^{ns}	44.9	1.17 [1.06-1.28]**
CKD	567 (6.5)	299 (7.6)	44.2	1.15 [0.79-1.54] ^{ns}	56.3	1.47 [1.24-1.69]****	52.4	1.37 [1.23-1.51]****
Smoker	952 (10.8)	446 (11.3)	44.4	1.16 [0.97-1.35] ^{ns}	47.1	1.23 [1.07-1.39]**	47.7	1.24 [1.12-1.38]****

Asthma	222 (2.5)	68 (1.7)	22.6	0.59 [0.30-1.04] ^{ns}	27.7	0.72 [0.48-1.04] ^{ns}	34.1	0.89 [0.69-1.12] ^{ns}
COPD	1,298 (14.8)	573 (14.5)	45.2	1.18 [1.01-1.36] [*]	45.2	1.18 [1.05-1.31] ^{**}	43.1	1.13 [1.02-1.24] [*]
ImmunoS	244 (2.8)	124 (3.1)	50.0	1.30 [0.93-1.68] ^{ns}	50.0	1.30 [0.99-1.62] ^{ns}	51.5	1.34 [1.12-1.57] ^{**}
Other	654 (7.5)	353 (8.9)	55.8	1.45 [1.21-1.70] ^{***}	54.9	1.43 [1.24-1.63] ^{****}	52.9	1.38 [1.23-1.53] ^{****}
Individuals w/comorb ^b	8,776 (100)	3,950 (100)	44.0	1.15 [1.08-1.21] ^{****}	45.3	1.18 [1.11-1.25] ^{****}	46.6	1.22 [1.14-1.30] ^{****}

^a All RRs were calculated against individuals with no comorbidities, in the same age-group, excluding individuals with unknown comorbidity status, **** p<0.0001; *** p<0.001; ** p<0.01; * p<0.05; ns, not significant; CI, confidence interval. ^b Some patients had more than one comorbidity, thus the sum of comorbidities (n and %) is larger than the individuals with comorbidity (w/comorb). Percents were calculated using “individuals w/comorbidity” as 100%.

Table S7. Frequency of the 23 most common comorbidity combinations by age group, in Mexico until Sept/12/2020 (second cutoff).

Comorbidity	20-39 yo		40-59 yo		60-79 yo		≥80 yo	
	Cases (%)	Deaths (%)	Cases (%)	Deaths (%)	Cases(%)	Deaths (%)	Cases (%)	Deaths (%)
No comorb.	173,011(69.8)	1,420(36.5)	129,754(50.0)	7,141(29.6)	33,694(30.1)	8,068(23.6)	4,580(26.80)	1,786(23.5)
DM-HT	881 (0.4)	85 (2.18)	10,769 (4.2)	2,022 (8.4)	13,436 (12.0)	4,602(13.4)	1,992(11.7)	928(12.21)
DM-obesity	1,444 (0.6)	109 (2.80)	4,822 (1.86)	709 (2.94)	1,847 (1.65)	639 (1.87)	110 (0.64)	57 (0.75)
Obesity-HT	2,680 (1.1)	118 (3.03)	8,831 (3.40)	1,082 (4.5)	4,167 (3.72)	1,354(3.95)	440 (2.57)	194 (2.55)
DM-CKD	70 (0.03)	15 (0.39)	272 (0.10)	110 (0.46)	325 (0.29)	171 (0.50)	32 (0.19)	14 (0.18)
HT-CKD	450 (0.18)	106 (2.72)	555 (0.21)	175 (0.73)	465 (0.42)	191 (0.56)	143 (0.84)	80 (1.05)
Obesity-CKD	98 (0.04)	7 (0.18)	111 (0.04)	22 (0.09)	48 (0.04)	19 (0.06)	2 (0.01)	1 (0.01)
CKD-ImmunoS	70 (0.03)	15 (0.39)	41 (0.02)	9 (0.04)	7 (0.01)	2 (0.01)	3 (0.02)	1 (0.01)
DM-smoker	267 (0.11)	18 (0.46)	1,089 (0.42)	160 (0.66)	621 (0.55)	221 (0.65)	72 (0.42)	43 (0.57)
HT-smoker	338 (0.14)	14 (0.36)	1,047 (0.40)	106 (0.44)	829 (0.74)	256 (0.75)	191(1.12)	86 (1.13)
Ob-smoker	4,208 (1.70)	85 (2.18)	2,929 (1.1)	298 (1.24)	482 (0.43)	149 (0.43)	30 (0.18)	18 (0.24)
DM-COPD	23 (0.01)	2 (0.05)	160 (0.06)	32 (0.13)	346 (0.31)	139 (0.41)	91 (0.53)	42 (0.55)
HT-COPD	25 (0.01)	2 (0.05)	212 (0.08)	38 (0.16)	564 (0.50)	216 (0.63)	285 (1.67)	142 (1.87)
Ob-COPD	57 (0.02)	2 (0.05)	180 (0.07)	29 (0.12)	161 (0.14)	50 (0.15)	35 (0.20)	13 (0.17)
Ob-asthma	1,127 (0.45)	31 (0.80)	922 (0.36)	68 (0.28)	131 (0.12)	30 (0.09)	9 (0.05)	0 (0.00)
HT-CVD	83 (0.03)	4 (0.10)	475 (0.18)	50 (0.21)	839 (0.75)	269 (0.79)	355 (2.08)	151 (1.99)
Ob-DM-HT	740 (0.30)	80 (2.05)	5,998 (2.31)	1,165 (4.8)	4,709 (4.2)	1,696 (5.0)	377 (2.21)	184 (2.42)
Ob-DM-HT-CKD	28 (0.01)	8 (0.21)	308 (0.12)	128 (0.53)	388 (0.35)	200 (0.58)	28 (0.16)	11 (0.14)
Ob-DM-HT-smkr	91 (0.04)	4 (0.10)	548 (0.21)	101 (0.42)	395 (0.35)	170 (0.50)	37 (0.22)	23 (0.30)
Ob-DM-HT-CVD	21 (0.01)	1 (0.03)	284 (0.11)	71 (0.29)	492 (0.44)	187 (0.55)	75 (0.44)	31 (0.41)
Ob-DM-HT-COPD	7 (0.003)	3 (0.08)	127 (0.05)	44 (0.18)	281 (0.25)	117 (0.34)	49 (0.29)	21 (0.28)
DM-HT-CKD	130 (0.05)	48 (1.23)	1,223 (0.47)	523 (2.17)	1,565 (1.40)	765 (2.23)	164 (0.96)	91 (1.20)
DM-HT-CKD-smkr	7 (0.003)	3 (0.08)	71 (0.03)	37 (0.15)	103 (0.09)	46 (0.13)	8 (0.05)	7 (0.09)
DM-HT-CVD	25 (0.01)	3 (0.08)	397 (0.15)	78 (0.32)	881 (0.79)	300 (0.88)	226 (1.32)	108 (1.4)

^aAll RRs were calculated against the population with no comorbidities in the age-group. Data are for the second cutoff date (Sept/12/2020), excluding individuals with unknown comorbidity status, as in Tables 1 and 2. **** p<0.0001; *** p<0.001; ** p<0.01; * p<0.05; ns, not significant; CI, confidence interval. Disease abbreviations are as Table 1.

Table S8. Years of life lost to premature COVID-19 mortality (YLL) in Mexico until end of study (Nov/2/2020), subdivided by gender and presence/absence of comorbidity.

	YLL ^a (%)			Number of people with YLL (%)			EXCESS YLL FROM COMORB. (% of total YLL) ^b
	No Comorbidity	With Comorbidity	Total YLL	No comorbidity	With Comorbidity	Total Individuals	
Females	75,033 (25.3)	221,209 (74.7)	296,242 (100)	4,555 (22.0)	16,170 (78.0)	20,725 (100)	146,176 (16.6)
Males	196,434 (33.7)	386,735 (66.3)	583,169 (100)	11,955 (31.0)	26,649 (69.0)	38,604 (100)	190,301 (21.6)
Total	271,467 (30.9)	607,944 (69.1)	879,411 (100)	16,510 (27.8)	42,819 (72.2)	59,329 (100)	336,477 (38.3)

^a For each deceased individual under age 70, YLL were calculated with the formula: $YLL = (70 \text{ years}) - (\text{age of deceased individual})$.

^b Excess YLL from the synergy between COVID-19 and the studied comorbidities in Mexico, were estimated by calculating the difference between YLL with and without comorbidity, with the formula: $\text{Excess YLL} = (\text{YLL with comorbidity}) - (\text{YLL without comorbidity})$. Percent in the last column were calculated using the total YLL (879,411) as 100%.

Table S9. Age stratified comparison of diabetes and obesity prevalence in Mexico vs the USA, as reported by health authorities.

Diabetes			
Mexico		USA	
Age group	% prevalence	Age group	% prevalence
20-39	1.8	18-44	3.0
40-59	12.8	45-64	13.8
>60	25.1	≥65	21.4
Total	10.3	Total	9.9

Obesity				
% prevalence				
Age group	Mexico		USA	
	males	females	males	females
5-11	20.1	15.0	18.5	
12-19	15.1	14.1		
20-29	24.1	26.2	34.8	36.5
30-39	34.0	39.0		
40-49	37.4	50.0	40.8	44.7
50-59	32.8	47.3		
60-69	31.1	48.4		
70-79	23.2	33.1	38.5	43.1
>80	12.5	17.6		

Supplementary Figures




Figure S1 Combinations of 2 comorbidities in COVID-19 deaths. (A) Combinations sorted by age, until Aug/6/2020 (first cutoff). This is a bar representation of a symmetric matrix (same diseases in columns and rows) to allow visualization of frequent combinations. (B) the RR_d of the 25-27 most common disease combinations are represented. Infrequent combinations (present in <0.2% of deaths in the age group) were excluded (blank squares) due to large 95% CI. A different RR_d scale was used for each age-group, because the RR_d at older ages is smaller.




Figure S2 Combinations of 3 or more comorbidities in COVID-19 deaths. (A) Combinations of pre-existing diseases, in individuals that died from COVID-19 and had **3 or more** comorbidities, depicted by age group, until Aug/6/2020 (first cutoff). This is a bar representation of a symmetric matrix (same diseases in columns and rows). **(B)** Percent of total COVID-19 cases and deaths that had the triad of obesity/diabetes/hypertension, with gender distribution \pm other disease(s).




Figure S3 Correspondence Analyses and Hierarchical Clustering of Principal Components (HCPC) of the Mexican COVID-19 datasets. Datasets were cutoff at: Aug/6 (A,C) and Sept/12/2020 (B,D,E,F). (A-B) The first two dimensions obtained by CA explain 98.5% of the total variation (94.9% for the first dimension and 3.6% for the second). Differences between cutoffs are observed until the 4th dimension. (C-D) CA asymmetric biplots created by representing age-groups (columns) in row space (comorbidities and outcomes). (E) HCPC found three clusters relating different comorbidities and outcomes. Favorable and adverse outcomes were located at opposite ends of the x-axis (largest dimension). Disease abbreviations are as in text. In (F) the same data was transposed to show the clustering of ages relative to the comorbidities and outcomes displayed in (E). Clusters reflect how the different comorbidities and outcomes are represented in different age groups. CA clusters were indistinguishable between cutoff dates.